Skip to main content
Clinical Trials/EUCTR2007-001987-55-ES
EUCTR2007-001987-55-ES
Active, not recruiting
Not Applicable

A randomised trial assessing whether preoperative chemotherapy improves outcome in high-risk operable colon cancer - FOxTROT

niversity Of Birmingham0 sites1,050 target enrollmentApril 14, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients with high-risk, operable colon cancer
Sponsor
niversity Of Birmingham
Enrollment
1050
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 14, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Histologically proven adenocarcinoma of the colon or high grade dysplasia on histology plus unequivocal radiological evidence of invasive cancer
  • \- A candidate for adjuvant oxaliplatin/ fluoropyrimidine chemotherapy based on:
  • Either radiological high risk (rT4 or rT3 tumour with extramural extension ? 5mm)
  • Or radiological intermediate risk (rT3 tumour with \<5mm extramural extension) and younger age/good general health
  • \- Patients presenting with acute colonic obstruction may enter the trial only after obstruction is relieved by a successful defunctioning stoma, and when recovered to a fitness level consistent with the other eligibility criteria
  • \- Adequate full blood count: WBC \>3\.0 x109/l; Plts \>100 x109/l. Anaemia (Hb \< 10\.0 g/dl) is not an exclusion, but should be corrected by transfusion prior to surgery and chemotherapy
  • \- Adequate renal biochemistry: GFR \>50 ml/min calculated by the Wright or Cockroft formula or EDTA clearance \>70 ml/min
  • \- Adequate hepatobiliary function: bilirubin \< 25 ?mol/l
  • \- Aged 18 or over
  • \- WHO performance status of 0, 1 or 2

Exclusion Criteria

  • \- Any patient for whom radiotherapy is advised by the MDT
  • \- Strong evidence of distant metastases or peritoneal nodules (M1\)
  • \- Peritonitis (secondary to perforated tumour)
  • \- Colonic obstruction that has not been defunctioned
  • \- Serious medical comorbidity, eg uncontrolled inflammatory bowel disease, uncontrolled angina or recent (\<6 months) MI
  • \- Another serious medical condition judged to compromise ability to tolerate neoadjuvant therapy and/or surgery
  • \- Any other malignant disease within the preceding 5 years with the exception of non\-melanomatous skin cancer, carcinoma in situ and early stage disease with a recurrence risk \<5%

Outcomes

Primary Outcomes

Not specified

Similar Trials